Fruquintinib, sintilimab, and chemo for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer that hasn't been treated yet, and it is HER2-negative or your HER2 status is not known.
- You are between 18 and 75 years old and are in generally good health (able to do daily activities).
- You have not had previous treatments that target VEGF (like bevacizumab) or PD-1/PD-L1 (like pembrolizumab).
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, kidney, and heart function are within safe limits.
- You are willing to use effective birth control during and for a time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and FOLFOX chemotherapy) as the first treatment for advanced gastric (stomach) cancer. The goal is to see if this combination is safe and effective in shrinking tumors or slowing the cancer's growth.
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
This trial tests a combination of two drugs (one targeted therapy and one immunotherapy) given with chemotherapy before and after surgery for stomach cancer that hasn't spread far. The goal is to see if this approach can improve outcomes for people with locally advanced disease.
Hear when a new Metastatic Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.